fda compounding semaglutide warning letters october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Warns Novo Nordisk on

Cardiovascular monitoring is particularly important

Feedback from the Canadian peptide community suggests that effects typically appear gradually

In particular, through structured programs or intensive lifestyle interventions, as demonstrated in the STEP 3 trial and supported by the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Start losing weight on semaglutide

Take your next scheduled dose the following day

After that, eligibility is based mainly on body weight and health status

GLP-1 and its analogs have emerged as significant therapeutic agents for managing metabolic disorders